When gene therapy meets adoptive cell therapy: better days ahead for cancer immunotherapy?

References

• van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science254(5038), 1643–1647 (1991).
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother.54(3), 187–207 (2005).
   PubMed Web of Science ®Google Scholar
• Adamina M, Oertli D. Antigen specific active immunotherapy: lessons from the first decade. Swiss Med. Wkly135(15–16), 212–221 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Shedding light on immunotherapy for cancer. N. Engl. J. Med.350(14), 1461–1463 (2004).
   PubMed Web of Science ®Google Scholar
• Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol.138(3), 989–995 (1987).
   PubMed Web of Science ®Google Scholar
• Gardner JM, Devoss JJ, Friedman RS et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science321(5890), 843–847 (2008).
   PubMed Web of Science ®Google Scholar
• Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med.199(2), 155–166 (2004).
   PubMed Web of Science ®Google Scholar
• Dutoit V, Rubio-Godoy V, Dietrich PY et al. Heterogeneous T-cell response to MAGE-A10(254–262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res.61(15), 5850–5856 (2001).
   PubMed Web of Science ®Google Scholar
• Schaed SG, Klimek VM, Panageas KS et al. T-cell responses against tyrosinase 368–376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res.8(5), 967–972 (2002).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte–macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol.21(21), 4016–4026 (2003).
   PubMed Web of Science ®Google Scholar
• Adamina M, Rosenthal R, Weber WP et al. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol. Ther.18, 651–659 (2010).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science298(5594), 850–854 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother.26(4), 332–342 (2003).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314(5796), 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood114(3), 535–546 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson LA, Heemskerk B, Powell DJ Jr et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol.177(9), 6548–6559 (2006).
   PubMedGoogle Scholar
• Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol.19(16), 3635–3648 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst.86(15), 1159–1166 (1994).
   PubMed Web of Science ®Google Scholar
• Khammari A, Labarriere N, Vignard V et al. Treatment of metastatic melanoma with autologous Mart-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol.129(12), 2835–2842 (2009).
   PubMed Web of Science ®Google Scholar
• Robbins PF, Dudley ME, Wunderlich J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol.173(12), 7125–7130 (2004).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol.23(10), 2346–2357 (2005).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol.26(32), 5233–5239 (2008).
   PubMed Web of Science ®Google Scholar
• Zajac P, Oertli D, Marti W et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther.14(16), 1497–1510 (2003).
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med.358(25), 2698–2703 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol.174(7), 4415–4423 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer8(4), 299–308 (2008).
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res.13(18 Pt 1), 5426–5435 (2007).
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di SA et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood110(7), 2620–2630 (2007).
   PubMed Web of Science ®Google Scholar
• Pinthus JH, Waks T, Malina V et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest114(12), 1774–1781 (2004).
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med.14(11), 1264–1270 (2008).
   PubMed Web of Science ®Google Scholar
• Schuetz F, Ehlert K, Ge Y et al. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol. Immunother.58(6), 887–900 (2009).
   PubMedGoogle Scholar
• Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol.24(31), 5060–5069 (2006).
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Spolski R, Paulos CM et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood111(11), 5326–5333 (2008).
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol6(8), 595–601 (2006).
   PubMed Web of Science ®Google Scholar